Skip to main content

Table 1 Demographic and baseline clinical characteristics of patients

From: Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Patient characteristic

ECOG 2 group

ECOG 0–1 group

Pb

EP arm (n = 31)

PC arm (n = 40)

pa

EP arm (n = 64)

PC arm (n = 56)

pa

Age

  

0.746

  

0.403

0.923

  < 65, y

23 (74.2%)

31 (77.5%)

 

51 (79.7%)

41 (73.2%)

  

  ≥ 65, y

8 (25.8%)

9 (22.5%)

 

13 (20.3%)

15 (26.8%)

  

 Median

56

58.5

 

59

56

  

 Range

32–70

42–70

 

33–70

39–70

  

Gender

  

0.627

  

0.382

0.308

 Male

25 (80.6%)

34 (85.0%)

 

55 (85.9%)

51 (91.1%)

  

 Female

6 (19.4%)

6 (15.0%)

 

9 (14.1%)

5 (8.9%)

  

Weight loss

  

0.276

  

0.878

0.674

  < 5%

17 (54.8%)

27 (67.5%)

 

42 (65.6%)

36 (64.3%)

  

  ≥ 5%

14 (45.2%)

13 (32.5%)

 

22 (34.4%)

20 (35.7%)

  

Smoking history

  

0.887

  

0.644

0.457

 Yes

22 (71.0%)

29 (72.5%)

 

48 (75.0%)

44 (78.6%)

  

 No

9 (29.0%)

11 (27.5%)

 

16 (25.0%)

12 (21.4%)

  

Pathology

  

0.912

  

0.500

0.082

 Squamous

23 (74.2%)

31 (77.5%)

 

42 (65.6%)

31 (55.4%)

  

 Adenocarcinoma

6 (19.4%)

6 (15.0%)

 

14 (21.9%)

15 (26.8%)

  

 Other

2 (6.5%)

3 (7.5%)

 

8 (12.5%)

10 (17.9%)

  

AJCC stage

  

0.747

  

0.566

0.326

 IIIA

6 (19.4%)

9 (22.5%)

 

19 (29.7%)

14 (25.0%)

  

 IIIB

25 (80.6%)

31 (77.5%)

 

45 (70.3%)

42 (75.0%)

  

Tumor stage

  

0.612

  

0.392

0.662

 T1

1 (3.2%)

0 (0.0%)

 

0 (0.0%)

0 (0.0%)

  

 T2

19 (61.3%)

22 (55.0%)

 

41 (64.1%)

33 (58.9%)

  

 T3

7 (22.6%)

13 (32.5%)

 

17 (26.6%)

13 (23.2%)

  

 T4

4 (12.9%)

5 (12.5%)

 

6 (9.4%)

10 (17.9%)

  

Nodal stage

  

0.594

  

0.564

0.409

 N2

9 (29.0%)

14 (35.0%)

 

23 (35.9%)

23 (41.1%)

  

 N3

22 (71.0%)

26 (65.0%)

 

41 (64.1%)

33 (58.9%)

  

Pre-RT pulmonary function

 FEV1 (L)c

2.09 (1.08–4.38)

1.99 (1.17–2.98)

0.638

2.23 (1.15–4.05)

2.07 (0.84–3.08)

0.266

0.277

 FEV1 (% predicted) c

65.1% (35.6–117.1%)

65.5% (42.4–103.6%)

0.656

70.3% (39.3–110.6%)

63.1% (22.3–96.7%)

0.133

0.607

  1. Abbreviations: EP etoposide/cisplatin, PC paclitaxel/carboplatin, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, FEV1 forced expiratory volume in 1 s
  2. ap value for testing the null hypothesis of no difference between patients receiving EP and PC chemotherapy
  3. bp value for testing the null hypothesis of no difference between ECOG 2 group and ECOG 0–1 group
  4. c Median (range)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us